Show simple item record

dc.contributor.authorEyles, Jim E
dc.contributor.authorVessillier, Sandrine
dc.contributor.authorJones, Anika
dc.contributor.authorStacey, Glyn
dc.contributor.authorSchneider, Christian K
dc.contributor.authorPrice, Jack
dc.date.accessioned2019-01-07T10:48:30Z
dc.date.available2019-01-07T10:48:30Z
dc.date.issued2018-12-17
dc.identifier.issn02682575
dc.identifier.doi10.1002/jctb.5829
dc.identifier.urihttp://hdl.handle.net/10033/621632
dc.relation.urlhttp://doi.wiley.com/10.1002/jctb.5829en_US
dc.rightsAttribution-NonCommercial-ShareAlike 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/4.0/*
dc.titleCell therapy products: focus on issues with manufacturing and quality control of chimeric antigen receptor T-cell therapiesen_US
dc.typeArticleen_US
dc.contributor.departmentTWINCORE, Zentrum für experimentelle und klinische Infektionsforschung GmbH,Feodor-Lynen Str. 7, 30625 Hannover, Germany.en_US
refterms.dateFOA2019-01-07T10:48:31Z
dc.source.journaltitleJournal of Chemical Technology & Biotechnology


Files in this item

Thumbnail
Name:
Eyles et al.pdf
Size:
389.3Kb
Format:
PDF
Description:
Open Access article

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-ShareAlike 4.0 International
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-ShareAlike 4.0 International